#$%^&*AU2020233707A120201015.pdf#####Abstract A solid dispersion and methods of preparing dry powder preparations comprising a nitrogen mustard selected from cyclophosphamide, bisulfan, chlorambucil, carmustin, melphalan, uramustine, ifosfamide, mechlorethamine, lumustine and bendamustine. The composition may also comprise a saccharine selected from mannitol, maltitol, sorbitol, erythritol, xylitol, lactitol, lactose, sucrose, glycose, maltose, trehalose and dextrose； and a polymer selected from vinylpyrrolidone, hydroxypropyl methyl cellulose, hydroxypropyl methyl cellulose acetate succinate (HPMC-AS), ethylene glycol, propylene glycol, propylene carbonate, vinyl acetate, vinyl propionate, vinyl caprolactame, cellulose acetate, ethyl cellulose, methyl methacrylate, methacrylic acid, polymers and co-polymers thereof. The composition may be formulated as an intravenous infusion solution and used for treating chronic lymphocytic leukemia, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, diffuse large B-cell lymphoma, breast cancer, small cell lung cancer, and/or an autoimmune disease.
